By Matthew Herper, Forbes Staff Deciding to bet on dexpramipexole, an experimental drug for ALS, was one of the first bets made by Biogen Idec chief executive George Scangos when he arrived at the company. Now the medicine has failed, and rather definitively, according to the company:

Today Biogen Idec (BIIB) reported top-line results […]

Source: FULL ARTICLE at Forbes Latest